Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada

OBJECTIVE: To report clinical characteristics and outcomes of people with multiple sclerosis (PwMS) who developed COVID-19 infection in Toronto, Canada. METHODS: Descriptive, retrospective, single-center study that included all known PwMS at the St. Michael's Hospital MS Clinic who had PCR-conf...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Jacqueline M., Jones, Ashley, Hohol, Marika, Krysko, Kristen M., Muccilli, Alexandra, Roll, Alexandra, Rotstein, Dalia, Schneider, Raphael, Selchen, Daniel, Vosoughi, Reza, Baral, Stefan D., Oh, Jiwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741626/
https://www.ncbi.nlm.nih.gov/pubmed/35030366
http://dx.doi.org/10.1016/j.msard.2022.103509
Descripción
Sumario:OBJECTIVE: To report clinical characteristics and outcomes of people with multiple sclerosis (PwMS) who developed COVID-19 infection in Toronto, Canada. METHODS: Descriptive, retrospective, single-center study that included all known PwMS at the St. Michael's Hospital MS Clinic who had PCR-confirmed COVID-19 infection between March 2020 and May 2021. RESULTS: Of 7000 PwMS in our clinic, 80 (1.1%) tested positive for SARS-CoV-2. Fifty-four (67.5%) were on disease-modifying therapy (DMT) without over-representation of any single treatment. Seventy-one patients (88.8%) had mild symptoms, but nine (11.3%) were hospitalized and one 70-year-old male patient not on treatment died. Of those hospitalized, one-third were treated with ocrelizumab. CONCLUSION: In Toronto, PwMS did not appear to have higher prevalence of COVID-19 infection compared to the general population, but disease severity may be affected by DMT use. Our findings add to the accumulating global data regarding COVID-19 infection in PwMS.

Ejemplares similares